Skip to content

Study · Randomized controlled trial · 2021

3 results

Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.

Dromain C, Loaiza-Bonilla A, Mirakhur B, Beveridge TJR, Fojo AT

The oncologist1 Feb 2021Cited by 13 (Europe PMC)

PMID33393112 (opens in a new tab)PMCIDPMC8018300 (opens in a new tab)DOI10.1002/onco.13669 (opens in a new tab)PepBankPUB-33393112
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In NET patients, lanreotide slowed tumor growth versus placebo (p = .00315), with a 389-day difference in doubling times.

    In plain wordsIn NET patients, lanreotide slowed tumor growth versus placebo, with a 389-day difference in doubling times.

    Peptide
    Lanreotide
    Outcome
    DecreaseTumor growth rate constant
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 4 weeksAs given in this study (human).

    Measurements

    Difference in tumor doubling time (lanreotide vs placebo)
    389 days
    slower growth rate g with lanreotide
    p value
    0.00315
    growth rate g, lanreotide vs placebo

    Source sentences

    Summary
    LAN-treated patients demonstrated significantly slower g than placebo recipients (p = .00315), a difference of 389 days in doubling times.
    1 context sentence
    Summary · context
    Using this approach, we analyzed data from the clinical trial CLARINET, evaluating lanreotide depot/autogel 120 mg/4 weeks (LAN) for treatment of neuroendocrine tumors (NETs).Methods and materialsComputed tomography imaging data from 97 LAN- and 101 placebo-treated patients from CLARINET we…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In NET patients, the tumor regression rate constant did not differ significantly between lanreotide and placebo.

    In plain wordsIn NET patients, tumor regression rates did not differ significantly between lanreotide and placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeTumor regression rate constant
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 4 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant difference was observed in d.
    1 context sentence
    Summary · context
    Using this approach, we analyzed data from the clinical trial CLARINET, evaluating lanreotide depot/autogel 120 mg/4 weeks (LAN) for treatment of neuroendocrine tumors (NETs).Methods and materialsComputed tomography imaging data from 97 LAN- and 101 placebo-treated patients from CLARINET we…
  3. 03HumanNon-randomized trialEfficacy outcome

    In NET patients receiving lanreotide for up to 700 days, the tumor growth rate constant did not change appreciably.

    In plain wordsIn NET patients receiving lanreotide for up to 700 days, tumor growth rates did not change appreciably.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedStability of tumor growth rate constant
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 4 weeks · up to 700 daysAs given in this study (human).

    Source sentences

    Summary
    Over periods of LAN administration up to 700 days, g did not change appreciably.
    1 context sentence
    Summary · context
    Using this approach, we analyzed data from the clinical trial CLARINET, evaluating lanreotide depot/autogel 120 mg/4 weeks (LAN) for treatment of neuroendocrine tumors (NETs).Methods and materialsComputed tomography imaging data from 97 LAN- and 101 placebo-treated patients from CLARINET we…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.